In a report released today, Geulah Livshits from Chardan Capital reiterated a Buy rating on Editas Medicine (EDIT – Research Report), with a price target of $60.00. The company’s shares closed last Wednesday at $18.69, close to its 52-week low of $9.59.
According to TipRanks.com, Livshits is a 5-star analyst with an average return of 26.2% and a 42.0% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Rocket Pharmaceuticals, and Crispr Therapeutics AG.
Editas Medicine has an analyst consensus of Hold, with a price target consensus of $21.91, a 24.9% upside from current levels. In a report released today, Credit Suisse also maintained a Buy rating on the stock with a $33.00 price target.
The company has a one-year high of $73.03 and a one-year low of $9.59. Currently, Editas Medicine has an average volume of 1.75M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.
Read More on EDIT:
- BMO Capital Keeps a Buy Rating on Host Hotels & Resorts (HST)
- Glaukos (GKOS) Gets a Buy Rating from BTIG
- Rosenblatt Securities Maintains a Hold Rating on Ansys (ANSS)
- The Necessity Retail REIT (RTL) Gets a Buy Rating from Colliers Securities
- 2 ‘Strong Buy’ Stocks J.P. Morgan Predicts Will Surge Over 40%